GRAMOCEF CV TAB

About

GRAMOCEF CV TAB combines Cefpodoxime, a third-generation cephalosporin antibiotic, with Clavulanic Acid, a potent beta-lactamase inhibitor. Cefpodoxime exerts its bactericidal effect by interfering with bacterial cell wall synthesis, offering a broad spectrum of activity against many common bacterial pathogens. The addition of clavulanic acid protects cefpodoxime from enzymatic degradation by a wide range of bacterial beta-lactamases, thereby restoring and extending its antibacterial spectrum to include resistant strains.

This combination is particularly valuable for treating infections caused by beta-lactamase-producing bacteria, which are increasingly prevalent. It is commonly prescribed for respiratory tract infections, urinary tract infections, and skin and soft tissue infections, providing an effective oral option against challenging pathogens and improving clinical outcomes in resistant cases.

Uses

• Treatment of community-acquired pneumonia.
• Management of acute bacterial exacerbations of chronic bronchitis.
• Therapy for uncomplicated urinary tract infections.
• Treatment of skin and soft tissue infections.

Directions For Use

Take this medication orally with food to enhance absorption, as directed by your physician. Do not stop taking it prematurely, even if symptoms improve.

Benefits

• Broad-spectrum antibacterial coverage.
• Effective against beta-lactamase producing bacteria.
• Improved efficacy against resistant strains.
• Good oral bioavailability.
• Convenient dosing regimen.
• Useful for various common infections.

Side Effects

• Diarrhea
• Nausea
• Vomiting
• Abdominal pain
• Headache
• Dizziness
• Rash
• Flatulence
• Vaginal candidiasis
• Pseudomembranous colitis (rare)
• Elevated liver enzymes
• Allergic reactions

Safety Measures

• Alcohol - No specific interaction with alcohol is known. However, alcohol may exacerbate gastrointestinal side effects.
• Pregnancy - Should be used during pregnancy only if clearly needed and after consulting a healthcare professional, as data on this specific combination is limited.
• Breastfeeding - Both components are excreted in small amounts into breast milk. Use with caution and monitor the infant for potential gastrointestinal disturbances or allergic reactions.
• Liver - Use with caution in patients with liver impairment. Monitor liver function during prolonged therapy, especially in those with pre-existing hepatic conditions.
• Kidney - Dose adjustment is necessary in patients with significant renal impairment to prevent accumulation and potential toxicity of both cefpodoxime and clavulanic acid.
• Lung - No specific contraindications or special precautions related to pre-existing lung conditions are generally noted for this combination.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.